Hsp90 inhibition sensitizes DLBCL cells to cisplatin Linnéa SchmidtIssa Ismail IssaKaren Dybkær Original Article Open access 21 February 2022 Pages: 431 - 440
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer Hai-yan PiaoJing-Lei QuYun-Peng Liu Original Article 23 February 2022 Pages: 441 - 449
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc Cheng DuXin GuanZhendong Zheng Original Article 24 February 2022 Pages: 451 - 458
Population pharmacokinetics of crenolanib in children and young adults with brain tumors Cora BisbeeOlivia CampagneClinton F. Stewart Original Article 25 February 2022 Pages: 459 - 468
Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma Zejia YangJipei LiaoHancai Dan Original Article 25 February 2022 Pages: 469 - 478
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma Ahmad Y. AbuhelwaSarah BadaouiAshley M. Hopkins Original Article Open access 28 February 2022 Pages: 479 - 485
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors Nusayba A. BagegniHaeseong ParkAndrea Wang-Gillam Original Article Open access 05 March 2022 Pages: 487 - 497
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers Enriqueta FelipVictor MorenoEmiliano Calvo Original Article Open access 17 March 2022 Pages: 499 - 514
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models Nikki DeAngelisCatherine FerranteRaluca I. Verona Original Article Open access 17 March 2022 Pages: 515 - 527
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study F. NelliA. VirtuosoE. M. Ruggeri Original Article 18 March 2022 Pages: 529 - 537
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report S. H. VerhulstE. BoerrigterP. Hamberg Short Communication 21 January 2022 Pages: 539 - 542
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients Takuto TakahashiRachael PearsonPamala A. Jacobson Short Communication 27 January 2022 Pages: 543 - 549
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321 J. GartrellJ. C. PanettaA. R. Weiss Short Communication 27 January 2022 Pages: 551 - 557
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil Yanjing HuangShenghui YangLing Gui Short Communication 08 February 2022 Pages: 559 - 564
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point Florent FerrerJonathan ChauvinJoseph Ciccolini Short Communication 11 February 2022 Pages: 565 - 569
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study Bei WangRong DengWhitney P. Kirschbrown Correction 24 September 2021 Pages: 571 - 572
